Phuong L Mai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5977948/publications.pdf

Version: 2024-02-01

53	3,590	186265	161849
papers	citations	28 h-index	54 g-index

56	56	56	6696
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome. Familial Cancer, 2022, 21, 333-336.	1.9	1
2	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	6.3	19
3	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
4	Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A Survey of Current Practice. JCO Precision Oncology, 2022, 6, e2100409.	3.0	5
5	Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology, 2022, , .	1.3	1
6	Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy. Breast Cancer Research and Treatment, 2022, 194, 393-401.	2.5	4
7	Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. Human Mutation, 2021, 42, 223-236.	2.5	81
8	Cancer incidence, patterns, and genotypeâ€“phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncology, The, 2021, 22, 1787-1798.	10.7	29
9	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
10	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI Cancer Spectrum, 2020, 4, pkz075.	2.9	11
11	Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians. Journal of Genetic Counseling, 2020, 29, 122-130.	1.6	16
12	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecologic Oncology, 2020, 156, 131-139.	1.4	8
13	Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. JNCI Cancer Spectrum, 2020, 4, pkaa063.	2.9	6
14	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
15	A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome. Genome Research, 2020, 30, 1170-1180.	5.5	4
16	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935.	2.5	7
17	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
18	Urgent cancer genetic counseling and testing for young, premenopausal women with breast cancer (BC): Impact on surgical decision-making for contralateral risk-reducing mastectomy.. Journal of Clinical Oncology, 2020, 38, 1533-1533.	1.6	0

#	Article	IF	Citations
19	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk â€“ Combined Results from Two Screening Trials. Clinical Cancer Research, 2017, 23, 3628-3637.	7.0	99
20	Estimating TP53 Mutation Carrier Probability in Families with Liâ€“Fraumeni Syndrome Using LFSPRO. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 837-844.	2.5	14
21	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 145, 122-129.	1.4	21
22	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
23	Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort. JAMA Oncology, 2017, 3, 1640.	7.1	43
24	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	7.1	148
25	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
26	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
27	Research participant interest in primary, secondary, and incidental genomic findings. Genetics in Medicine, 2016, 18, 1218-1225.	2.4	24
28	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
29	Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Liâ€Fraumeni syndrome cohort. Cancer, 2016, 122, 3673-3681.	4.1	346
30	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
31	Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Liâ€Fraumeni Syndrome. Journal of Genetic Counseling, 2016, 25, 529-542.	1.6	24
32	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Human Molecular Genetics, 2016, 25, 2256-2268.	2.9	106
33	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
34	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
35	Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. Journal of Clinical Investigation, 2016, 127, 132-136.	8.2	39
36	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26

#	Article	IF	Citations
37	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
38	Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	7.0	138
39	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
40	Germline TP53 Variants and Susceptibility to Osteosarcoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	109
41	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
42	The Fallopian Tube: From Back Stage to Center Stage. Cancer Prevention Research, 2015, 8, 339-341.	1.5	5
43	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
44	Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among BRCA1/2 carriers.. Health Psychology, 2015, 34, 709-717.	1.6	19
45	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
46	Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199. Journal of Clinical Oncology, 2014, 32, 3275-3283.	1.6	115
47	Awareness of Cancer Susceptibility Genetic Testing. American Journal of Preventive Medicine, 2014, 46, 440-448.	3.0	107
48	Challenges Related to Developing Serum-Based Biomarkers for Early Ovarian Cancer Detection. Cancer Prevention Research, 2011, 4, 303-306.	1.5	46
49	Confirmation of Family Cancer History Reported in a Population-Based Survey. Journal of the National Cancer Institute, 2011, 103, 788-797.	6.3	91
50	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 492-499.	1.6	42
51	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. Familial Cancer, 2009, 8, 451-456.	1.9	21
52	A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 594-604.	2.5	99
53	A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. Journal of Medical Case Reports, 2007, 1, 9.	0.8	9